Clinical Pharmacokinetics

, Volume 40, Issue 7, pp 523–537 | Cite as

Drug Interaction Studies with Esomeprazole, the (S)-Isomer of Omeprazole

  • Tommy Andersson
  • Mohammed Hassan-Alin
  • Göran Hasselgren
  • Kerstin Röhss
Review Articles Drug Interactions


Esomeprazole, the (S)-isomer of omeprazole, is the first proton pump inhibitor (PPI) developed as a single isomer for the treatment of patients with acid related diseases. Because of the extensive use of PPIs, the documentation of the potential for drug interactions with esomeprazole is of great importance.

Altered absorption or metabolism are 2 of the major mechanisms for drug-drug interactions. Since intragastric pH will increase with esomeprazole treatment, it can be hypothesised that the absorption of drugs with pH-sensitive absorption (e.g. digoxin and ketoconazole) may be affected.

Esomeprazole does not seem to have any potential to interact with drugs that are metabolised by cytochrome P450 (CYP) 1A2, 2A6, 2C9, 2D6 or 2E1. In drug interaction studies with diazepam, phenytoin and (R)-warfarin, it was shown that esomeprazole has the potential to interact with CYP2C19. The slightly altered metabolism of cisapride was also suggested to be the result of inhibition of a minor metabolic pathway for cisapride mediated by CYP2C19. Esomeprazole did not interact with the CYP3A4 substrates clarithromycin (2 studies) or quinidine. Since the slightly increased area under the concentration-time curve (AUC) of cisapride could be explained as an inhibition of CYP2C19, the data on these 3 CYP3A4 substrates indicate that esomeprazole does not have the potential to inhibit this enzyme.

The minor effects reported for diazepam, phenytoin, (R)-warfarin, and cisapride are unlikely to be of clinical relevance. Clarithromycin interacts with the metabolism of esomeprazole resulting in a doubling of the AUC of esomeprazole. The increased plasma concentrations of esomeprazole are unlikely to have any safety implications.

It can be concluded that the potential for drug-drug interactions with esomeprazole is low, and similar to that reported for omeprazole.


Warfarin Omeprazole Clarithromycin Quinidine Esomeprazole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



All studies were sponsored by AstraZeneca.


  1. 1.
    Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, and pantoprazole. Clin Pharmacokinet 1996; 31: 9–28CrossRefPubMedGoogle Scholar
  2. 2.
    Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143–54CrossRefPubMedGoogle Scholar
  3. 3.
    Andersson T, Holmberg J, Röhss K, et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45:369–75CrossRefPubMedGoogle Scholar
  4. 4.
    Andersson T, Bredberg E, Sunzel M, et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/Esomeprazole (E) and (R)-omeprazole (R-O) [abstract 5551]. Gastroenterology 2000; 118 (4 Pt II): A1210Google Scholar
  5. 5.
    Junghard O, Hassan-Alin M, Hasselgren G. The effect of AUC and Cmax of esomeprazole on acid secretion and intragastric pH [abstract 331]. Gastroenterology 2000; 118 (4 Pt II): A17CrossRefGoogle Scholar
  6. 6.
    Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861–7CrossRefPubMedGoogle Scholar
  7. 7.
    Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58CrossRefPubMedGoogle Scholar
  8. 8.
    Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994; 8 Suppl. 1: 33–8PubMedGoogle Scholar
  9. 9.
    Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13: 27–36CrossRefPubMedGoogle Scholar
  10. 10.
    Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twentyfour-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1: 239–51CrossRefPubMedGoogle Scholar
  11. 11.
    Ekenved G, Elofsson R, Sölvell L. Bioavailability studies on a buffered acetylsalicylic acid preparation. Acta Pharmacol Suecia 1975; 12: 323–32Google Scholar
  12. 12.
    Mayersohn M. Physiological factors that modify systemic drug availability and pharmacologic response in clinical practice. In: Blanchard J, Brodie BB, Sawchuk RJ, editors. Principles and perspectives in drug bioavailability. Basel: Karger, 1979: 211–73Google Scholar
  13. 13.
    Äbelö A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966–72PubMedGoogle Scholar
  14. 14.
    An interaction study between H 199/18, amoxicillin and clarithromycin in healthy male and female subjects (Study no. SH-QBE 0034). AstraZeneca, 1998 (Data on file)Google Scholar
  15. 15.
    An interaction study between H 199/18 b.i.d., amoxicillin b.i.d. and clarithromycin b.i.d. in healthy male and female subjects (Study no. SH-QBE-0040). AstraZeneca, 1998 (Data on file)Google Scholar
  16. 16.
    Pharmacokinetics of diazepam with and without co-administration of H 199/18 sodium in healthy volunteers (Study no. SH-QBE-SH-QBE-0003). AstraZeneca, 1997 (Data on file)Google Scholar
  17. 17.
    Pharmacokinetics of phenytoin with and without co-administration of H 199/18 sodium in healthy volunteers (Study no. SH-QBE-0004). AstraZeneca, 1997 (Data on file)Google Scholar
  18. 18.
    An interaction study between H 199/18 and phenytoin in healthy male and female subjects (Study no. SH-QBE-0032). AstraZeneca, 1998 (Data on file)Google Scholar
  19. 19.
    An interaction study between H 199/18 and phenytoin in epileptic patients (Study no. AM-201). AstraZeneca, 1999 (Data on file)Google Scholar
  20. 20.
    An interaction study between H 199/18 and warfarin in warfarin treated patients (Study no. SH-QBE-0038). AstraZeneca, 1999 (Data on file)Google Scholar
  21. 21.
    Pharmacokientics of quinidine with and without co-administration of H 199/18 sodium in healthy volunteers (Study no. SH-QBE-0005). AstraZeneca, 1997 (Data on file)Google Scholar
  22. 22.
    An interaction study between H 199/18 and cisapride in healthy male and female subjects (Study no. SH-QBE-0036). AstraZeneca, 1999 (Data on file)Google Scholar
  23. 23.
    Andersson T, Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131–7CrossRefPubMedGoogle Scholar
  24. 24.
    Yasumori T, Nagata K, Yang SK, et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993; 3: 291–301CrossRefPubMedGoogle Scholar
  25. 25.
    Ieiri I, Mamiya K, Urae A, et al. Stereoselective 4′-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br J Clin Pharmacol 1997; 43(4): 441–5CrossRefPubMedGoogle Scholar
  26. 26.
    Kaminsky LS, de Morais SMF, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993; 43: 234–9PubMedGoogle Scholar
  27. 27.
    Desta Z, Soukhova N, Mahal SK, et al. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000; 28: 789–800PubMedGoogle Scholar
  28. 28.
    Guengerich FP, Müller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986; 30: 287–95PubMedGoogle Scholar
  29. 29.
    Rodrigues AD, Roberts EM, Mulford DJ, et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997; 25(5): 623–30PubMedGoogle Scholar
  30. 30.
    Center for Drug Evaluation and Research (CDER). Guidance for Industry. Labeling guidance for cisapride oral suspension. Bethesda (MD): Center for Drug Evaluation and Research, 1997 Sep: 1–11Google Scholar
  31. 31.
    Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47(1): 79–85CrossRefPubMedGoogle Scholar
  32. 32.
    Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235–41PubMedGoogle Scholar
  33. 33.
    Greenblatt DJ, Darrell R, Abernethy DR, et al. Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 1984; 310(25): 1639–43CrossRefPubMedGoogle Scholar
  34. 34.
    Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543–5CrossRefPubMedGoogle Scholar
  35. 35.
    Bachmann KA, Sullivan TJ, Jauregui L, et al Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Pharmacol 1993; 36: 380–2CrossRefPubMedGoogle Scholar
  36. 36.
    Andersson T, Lagerström P-O, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 1990; 12: 329–33CrossRefPubMedGoogle Scholar
  37. 37.
    Sutfin T, Balmer K, Boström H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11(2): 176–84CrossRefPubMedGoogle Scholar
  38. 38.
    Unge P, Svedberg L-E, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509–12CrossRefPubMedGoogle Scholar
  39. 39.
    Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335(4): 290–1CrossRefPubMedGoogle Scholar
  40. 40.
    Hasselgren B, Claar-Nilsson C, Hasselgren G, et al. Studies in healthy volunteers do not show any electrocardiographic effects with esomeprazole. Clin Drug Invest 2000; 20(6): 425–31CrossRefGoogle Scholar
  41. 41.
    van Haarst AD, Gerben AE, van’t Klooster GAE, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 64: 542–6CrossRefPubMedGoogle Scholar
  42. 42.
    Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665–70CrossRefPubMedGoogle Scholar
  43. 43.
    Andersson T, Lundborg P, Regårdh CG. Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharmacol 1991; 40: 61–5CrossRefPubMedGoogle Scholar
  44. 44.
    Lennard MS, Silas JH, Freestone S, et al. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1982; 14: 301–3CrossRefPubMedGoogle Scholar
  45. 45.
    Jönsson K-Å, Jones AW, Boström H, et al. Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. Eur J Clin Pharmacol 1992; 42: 209–12CrossRefPubMedGoogle Scholar
  46. 46.
    Guengerich FP, Kim D-H, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168–79CrossRefPubMedGoogle Scholar
  47. 47.
    Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991; 35(9): 1765–71CrossRefPubMedGoogle Scholar
  48. 48.
    Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39(8): 1671–5CrossRefPubMedGoogle Scholar
  49. 49.
    Oosterhuis B, Jonkman JHG, Andersson T, et al. Minor effect ofmultiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991; 32: 569–72CrossRefPubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Tommy Andersson
    • 1
  • Mohammed Hassan-Alin
    • 2
  • Göran Hasselgren
    • 2
  • Kerstin Röhss
    • 2
  1. 1.Clinical PharmacologyAstraZeneca LPWayneUSA
  2. 2.Clinical ResearchAstraZeneca MolndalMolndalSweden

Personalised recommendations